Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations{star, open}

Research in Social and Administrative Pharmacy

Volumn 1, Issue 1, 2005, Pages 77-100

  Barner, Jamie C ^a   Branvold, Andrea ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Hormone replacement therapy; Menopause; Pharmacy services; Willingness to pay

Indexed keywords

ARTICLE; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; MENOPAUSE; MIDDLE AGED; PATIENT EDUCATION; PATIENT SATISFACTION; PHARMACIST; PHARMACY; PROFESSIONAL COMPETENCE;

FEMALE; FINANCING, PERSONAL; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL COMPETENCE; SEVERITY OF ILLNESS INDEX;

EID: 33745947870     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2004.12.008     Document Type: Article

References (42)

1. Sulak P.J. The perimenopause: a critical time in a woman's life. Int J Fertil Menopausal Stud 41 (1996) 85-89
2. Shepherd J.E. Effects of estrogen on cognition, mood, and degenerative brain diseases. J Am Pharm Assoc 41 (2001) 221-228
3. Archer D.F., Gass M.S., Gelfand M.M., et al. Clinical challenges of perimenopause: consensus opinion of the North American Menopause Society. Menopause 7 (2000) 5-12
4. Whitehead M.I. General principles of administration of hormone replacement therapy: indications and contraindications, routes of administration, treatment schedules. In: Fraser I.S., Jansen R.P.S., Lobo R.A., et al. (Eds). Estrogens and Progestogens in Clinical Practice. 1st ed. (2000), Harcourt Publishers Ltd, Edinburgh 667-686
5. Clinical Synthesis Panel on HRT. Clinical synthesis conference: hormone replacement therapy. Lancet 354 (1999) 152-155
6. Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?. J Clin Pharmacol 37 (1997) 1087-1099
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
8. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117 (1992) 1016-1037
9. Chow M.S. Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. J Clin Pharmacol 35 suppl (1995) 11S-17S
10. Stumpf P.G., and Trolice M.P. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 21 (1994) 219-226
11. Ryan P.J., Harrison R., Blake G.M., and Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 99 (1992) 325-328
12. Torgerson D.J., Donaldson C., Russell I.T., et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol 59 (1995) 57-60
13. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center. Maturitas 20 (1995) 91-99
14. Schiff I., Rebar R.W., Cramer J.A., et al. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of the North American Menopause Society. Menopause 5 (1995) 69-76
15. Ravnikar V.A. Compliance with hormone therapy. Am J Obstet Gynecol 156 (1987) 1332-1334
16. Ferguson K.J., Hoegh C., and Johnson S. Estrogen replacement therapy: a survey of women's knowledge and attitudes. Arch Int Med 149 (1989) 133-136
17. Nachtigall L.E. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 75 (1990) S77-S80
18. Conboy L., Domar A., and O'Connell E. Women at mid-life: symptoms, attitudes, and choices, and internet based survey. Maturitas 38 (2001) 129-136
19. Kaufert P., Boggs P., Etinger B., et al. Women and menopause: beliefs, attitudes and behaviors. The North American Menopause Society 1997 menopause survey. Menopause 5 4 (1998) 197-202
20. Connelly M.T., Ferrari N., Hagen N., et al. Patient-identified needs for hormone replacement therapy counseling: a qualitative study. Ann Intern Med 131 (1999) 265-268
21. American Pharmaceutical Asssociation. APhA national survey: willingness of consumers to pay for pharmacists' clinical services. Am Pharm NS23 (1983) 314-327
22. Larson R. Patients' willingness to pay for pharmaceutical care. J Am Pharm Assoc 40 (2000) 618-624
23. Suh D.C. Consumers' willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc 40 (2000) 818-826
24. Gore P.R., and Madhavan S. Consumers' preference and willingness to pay for pharmacist counseling of non-prescription medicines. J Clin Pharm Ther 19 (1994) 17-25
25. Reutzel T.J., and Furmaga E. Willingness to pay for pharmacist services in a veterans administration hospital. J Res Pharm Econ 5 (1993) 89-114
26. Einarson T.R., Bootman J.L., Larson L.N., et al. Blood level testing in a community pharmacy: consumer demand and financial feasibility. Am Pharm NS28 (1988) 76-79
27. Barner J.C. Patient willingness to pay for diabetes disease state management programs. J Manag Pharm Care 1 (2001) 85-96
28. Barner J.C., Mason H.L., and Murray M.D. Assessment of asthma patients' willingness to pay for and willingness to give time to an asthma self-management program. Clin Ther 21 (1999) 878-894
29. Blumenschein K., and Johannesson M. Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature. Clin Ther 21 (1999) 1402-1417
30. Johannesson M., and Jonsson B. Willingness to pay for antihypertensive therapy-results of a Swedish pilot study. J Health Econ 10 (1991) 461-474
31. Johannesson M., and Johansson P.O. Willingness to pay for antihypertensive therapy-further results. J Health Econ 12 (1993) 95-108
32. Ramsey S., Sullivan S., Psaty B., and Patrick D. Willingness to pay for antihypertensive care: evidence from a staff-model HMO. Soc Sci Med 44 (1997) 1911-1917
33. Ryan M., Ratcliffe J., and Tucker J. Using willingness to pay to value alternative models of antenatal care. Soc Sci Med 44 (1997) 371-380
34. Nunnally J.C. Psychometric Theory (1978), McGraw-Hill Book Company, New York, NY
35. Kuntz R., and Remmert R. A new trend in pharmacy practice: private consultations. Int J Pharm Compound 5 (2000) 170-172
36. Nau D.P., Reid L.D., Lipowski E.E., et al. Patients' perceptions of the benefits of pharmaceutical care. J Am Pharm Assoc 40 (2000) 36-40
37. Cerulli J. Patients' perceptions of independent community pharmacists. J Am Pharm Assoc 42 (2002) 279-282
38. Johannesson M., Johansson P.O., Kristrom B., et al. Willingness to pay for lipid lowering: a health production function approach. Appl Econ 25 (1993) 1023-1031
39. Neumann P.J., and Johannesson M. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care 32 (1994) 686-699
40. North American Menopause Society. The Menopause Core Curriculum Study Guide. October 2002, Section A. Available at: http://www.menopause.org/NR/rdonlyres/9E4D788A-5DD6-4FDB-8D02-2293F7760D7C/0/sga.pdf. Accessed on November 9, 2004.
41. U.S. National Oceanic and Atmospheric Administration. Report of the NOAA panel on contingent valuation. Fed Regist 58 (1993) 4602-4614
42. Blumenschein K., Johannesson M., Blomquist G.C., et al. Experimental results on expressed certainty and hypothetical bias in contingent valuation. South Econ J 65 (1998) 169-177